logo

For the Inventor, By the Inventor

Tokushima, Japan

Delta-Fly Pharma, Inc.


USPTO Granted Patents = 14


Trademarks = 2

Forward Citations = 2

Loading Chart...
Loading Chart...

10 inventors (with patents filed for the assignee):

goldMedal Tatsuhiro Ishida (7 out of 11 patents)

silverMedal Kiyoshi Eshima (7 out of 9 patents)

bronzeMedal Hiromi Wada (6 out of 10 patents)

4.  Masakazu Fukushima (3 out of 43 patents)

5.  Cheng Long Huang (2 out of 2 patents)

6.  Ryo Oyama (1 out of 1 patent)

7.  Shotaro Watanabe (1 out of 1 patent)

8.  Takahiro Hatakeyama (1 out of 1 patent)

9.  Shozo Yamada (1 out of 13 patents)

10.  Reo Hamaguchi (1 out of 1 patent)

11.  Kazuhito Arakawa (1 patent)

12.  Eshima Kiyoshi (0 patent)

13.  Ishida Tatsuhiro (0 patent)

14.  Wada Hiromi (0 patent)

15.  Hamaguchi Reo (0 patent)


14 patents:

1. 11957701 - Therapy and new therapeutic agent for blood cancer (2024-04-16),
2. 11684582 - Method for stabilizing humidity-sensitive pharmaceutical substance and stabilized preparation thereof (2023-06-27),
3. 11622976 - Urine alkali agent useful for treatment of cancer patient (2023-04-11),
4. 11524078 - Water-soluble macromolecular derivative of Venetoclax (2022-12-13),
5. 11246847 - Anticancer drug effect enhancer (2022-02-15),
6. 11185517 - Pharmaceutical composition for treatment or remission of chronic myelogenous leukemia (2021-11-30),
7. 10293019 - Pharmaceutical composition for treatment of or remission in elderly or terminal cancer patient (2019-05-21),
8. 10111955 - PEG derivative (2018-10-30),
9. 9855345 - Method for producing lipoplex for topical administration and antitumor agent using such lipoplex (2018-01-02),
10. 9745583 - Liposome for topical administration and application thereof (2017-08-29),
11. 8889699 - 5-fluorouracil derivative (2014-11-18),
12. 8592572 - Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof (2013-11-26),
13. 8524876 - RNAi molecule targeting thymidylate synthase and application thereof (2013-09-03),
14. 8377905 - Stable crystal of 1-(2'-cyano-2′-deoxy-β-D-arabinofuranosyl)cytosine monohydrochloride (2013-02-19),
Company Overview
Delta-Fly Pharma, Inc. is a biotechnology company based in Tokushima, Japan, specializing in the development of innovative therapies for various medical conditions. The organization focuses on advanced drug delivery systems and novel pharmaceutical formulations, aiming to enhance treatment efficacy and patient outcomes. With a commitment to research and development, Delta-Fly Pharma leverages cutting-edge technology to address unmet medical needs, contributing to the global healthcare landscape through its specialized expertise.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Delta-Fly Pharma, Inc. USPTO Patent Assignee Logo
14 Patents

#11 in Tokushima

#3,580 in Japan

#42,249 in the World

Tokushima, JP
Tokushima, Japan

Delta-Fly Pharma, Inc.

Forward Citations = 2

10 inventors:

goldMedal Tatsuhiro Ishida (7 out of 11 patents)

silverMedal Kiyoshi Eshima (7 out of 9 patents)

bronzeMedal Hiromi Wada (6 out of 10 patents)

4.  Masakazu Fukushima (3 out of 43 patents)

5.  Cheng Long Huang (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Delta-Fly Pharma, Inc.. Retrieved from https://idiyas.com/company/delta-fly-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…